Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study. [electronic resource]
Producer: 20131125Description: 3688-95 p. digitalISSN:- 1527-7755
- Adult
- Aged
- Aged, 80 and over
- Angiogenesis Inhibitors -- therapeutic use
- Antineoplastic Agents -- therapeutic use
- Boronic Acids -- therapeutic use
- Bortezomib
- Disease Progression
- Female
- Humans
- Lenalidomide
- Lymphoma, Mantle-Cell -- drug therapy
- Male
- Middle Aged
- Pyrazines -- therapeutic use
- Recurrence
- Thalidomide -- adverse effects
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.